Bromantane

Source: Wikipedia, the free encyclopedia.

Bromantane
Clinical data
Trade namesLadasten
Other namesBromantan; Bromontan; ADK-709; N-(2-Adamantyl)-4-bromoaniline; N-(2-Adamantyl)-N-(4-Bromophenyl)amine; N-(4-Bromophenyl)-2-adamantanamine
Routes of
administration		By mouth
ATC code
  • None
Legal status
Legal status
  • US: Unscheduled, not FDA approved
  • Rx-only (RU)
Pharmacokinetic data
Bioavailability27.5%[citation needed]
Onset of action1.5–2 hours (PO)
Elimination half-life11.21 hours (in humans),[1]
7 hours (in rats)[2]
Duration of action8–12 hours (PO)
Identifiers
  • N-(4-Bromophenyl)adamantan-2-amine
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
ECHA InfoCard100.213.907 Edit this at Wikidata
Chemical and physical data
FormulaC16H20BrN
Molar mass306.247 g·mol−1
3D model (JSmol)
  • C1C2CC3CC1CC(C2)C3NC4=CC=C(C=C4)Br
  • InChI=1S/C16H20BrN/c17-14-1-3-15(4-2-14)18-16-12-6-10-5-11(8-12)9-13(16)7-10/h1-4,10-13,16,18H,5-9H2 ☒N
  • Key:LWJALJDRFBXHKX-UHFFFAOYSA-N ☒N
  (verify)

Bromantane, sold under the brand name Ladasten, is an atypical central nervous system (CNS) stimulant and anxiolytic drug of the adamantane family that is related to amantadine and memantine. Medically, it is approved in Russia for the treatment of neurasthenia. Although the effects of bromantane have been determined to be dependent on the dopaminergic and possibly serotonergic neurotransmitter systems, its exact mechanism of action is unknown,[3][4] and is distinct in its properties relative to typical stimulants such as amphetamine. Bromantane has sometimes been described as an actoprotector (synthetic adaptogen).[5][6]

Effects

Clinical research

The therapeutic effects of bromantane in asthenia are said to onset within 1–3 days.[7] It has been proposed that the combination of stimulant and anxiolytic activity may give bromantane special efficacy in the treatment of asthenia.[8]

In a large-scale, multi-center clinical trial of 728 patients diagnosed with asthenia in Russia, bromantane was given for 28 days at a daily dose of 50 mg or 100 mg.[7] The study concluded with an impression score of 76.0% on the CGI-S and 90.8% on the CGI-I for bromantane, indicating that it is broadly applicable and highly effective.[7] The therapeutic benefit against asthenia was observed to still be present one month after discontinuation of the drug.[7] 3% of patients experienced side effects; though none were considered serious; and 0.8% of patients discontinued treatment due to side effects.[7] Bromantane was also noted to normalize the sleep-wake cycle.[7]

Psychotropic effects

Bromantane is described primarily as a mild stimulant[9] and anxiolytic.[8] It is also said to possess anti-asthenic properties.[10][8] Bromantane is reported to improve physical and mental performance, hence it could be considered a performance-enhancing drug.[10]

Bromantane has been found to lower the levels of pro-inflammatory cytokines IL-6, IL-17 and IL-4 and to normalize behavior in animal models of depression, and may possess clinical efficacy as an antidepressant.[11][12][13] It has also been found to increase sexual receptivity and proceptivity in rats of both sexes, which was attributed to its dopaminergic actions.[14] It has been proposed that bromantane may suppress prolactin levels by virtue of its dopaminergic properties as well.[15] Bromantane has been found to "agonize" amphetamine-induced stereotypies in vivo, suggesting that it might potentiate certain effects of other stimulants.[4]

The stimulant effects of bromantane onset gradually within 1.5–2 hours and last for 8–12 hours when taken orally.[9]

Pharmacology

Pharmacodynamics

Dopamine synthesis enhancement

Although it is frequently labeled as a stimulant, bromantane is distinct in its pharmacology and effects relative to typical stimulants, such as the phenethylamines (e.g., amphetamine and its derivatives) and their structural analogues (e.g., methylphenidate, cocaine, mesocarb, etc.).[16][17] Whereas the latter directly act on the dopamine transporter (DAT) to inhibit the reuptake and/or induce the release of dopamine, bromantane instead acts via indirect genomic mechanisms to produce a rapid, pronounced, and long-lasting upregulation in a variety of brain regions of the expression of tyrosine hydroxylase (TH) and aromatic L-amino acid decarboxylase (AAAD) (also known as DOPA decarboxylase), key enzymes in the dopamine biosynthesis pathway.[9][18][19] For instance, a single dose of bromantane produces a 2–2.5 fold increase in TH expression in the rat hypothalamus 1.5–2 hours post-administration.[20] The biosynthesis and release of dopamine subsequently increase in close correlation with TH and AAAD upregulation.[9][18][19] Enhancement of dopaminergic neurotransmission is observed in the hypothalamus, striatum, ventral tegmental area, nucleus accumbens, and other regions.[9][18][19] As such, the key mechanism of the pharmacological activity and psychostimulant effects of bromantane is activation of the de novo synthesis of dopamine via modulation of gene expression.[18]

A selection of quoted excerpts from the medical literature detail the differences between bromantane and typical stimulants:[10][9][16]

  • "Bromantane [does] not concede well-known psychostimulant of phenylalkylamine structure and its analogs (amphetamine, [mesocarb], [methylphenidate], etc.) by specific activity. In contrast, bromantane has neither addictive potential nor reveals redundant and exhausting activation of sympaticoadrenergic system, or decelerates the restoring of work capacity at preventive application before forthcoming activity in complicated conditions (hypoxia, high environmental temperature, physical overfatigue, emotional stress, etc.). Bromantane has no prohypoxic activity."
  • "The use of the drug, in contrast to the action of a typical psychostimulant, is not associated with the phenomenon of hyperstimulation and causes no consequences such as functional exhaustion of the body."
  • "Bromantane administration in therapeutic doses is characterized by the almost full absence of side effects including manifestations of withdrawal syndrome and hyperstimulation."
  • "[Bromantane] has low peripheral sympathomimetic effects. Moreover, no signs of [bromantane] dependence and withdrawal symptoms were found."

Bromantane is well tolerated and elicits few side effects (including peripheral sympathomimetic effects and hyperstimulation), does not appear to produce tolerance or dependence, has not been associated with withdrawal symptoms upon discontinuation, and displays an absence of addiction potential, contrary to typical stimulants.[10][8] In accordance with human findings, animals exposed to bromantane for extended periods of time do not appear to develop tolerance or dependence.[21]

The precise direct molecular mechanism of action by which bromantane ultimately acts as a dopamine synthesis enhancer is unknown.[3][4] However, it has been determined that activation of certain cAMP-, Ca2+-, and phospholipid-dependent protein kinases such as protein kinase A and especially protein kinase C corresponds with the manifestation of the pharmacological effects of bromantane.[17][22] Bromantane may activate intracellular signaling cascades by some mechanism (e.g., agonizing some as-yet-undetermined receptor) to in turn activate protein kinases, which in turn cause increased transcription of TH and AAAD.[17][22]

The related drugs amantadine and memantine also have many properties similar to those of bromantane.[23][24][25]

Researchers discovered that amantadine and memantine bind to and act as agonists of the σ1 receptor (Ki = 7.44 μM and 2.60 μM, respectively) and that activation of the σ1 receptor is involved in the central dopaminergic effects of amantadine at therapeutically relevant concentrations; the authors of the study stated that this could also be the mechanism of action of bromantane, as it is in the same family of structurally related compounds and evidence suggests a role of dopamine in its effects. But this could also be seen as evidence of the contrary since bromantane has effects that are distinctly different from amantadine and memantine.

Monoamine reuptake inhibition

Bromantane was once thought to act as a reuptake inhibitor of serotonin and dopamine.[3][16][26] While bromantane can inhibit the reuptake of serotonin, dopamine, and to a lesser extent norepinephrine in vitro in rat brain tissue, the concentrations required to do so are extremely high (50–500 μM) and likely not clinically relevant.[16][26] Although one study found an IC50 for dopamine transport of 3.56 μM, relative to 28.66 nM for mesocarb; neither drug affected serotonin transport at the tested concentrations, in contrast.[27] The lack of typical stimulant-like effects and adverse effects seen with bromantane may help corroborate the notion that it is not acting significantly as a monoamine reuptake inhibitor, but rather via a different mechanism.

Other actions

Bromantane has been found to increase the expression of neurotrophins including brain-derived neurotrophic factor and nerve growth factor in certain rat brain areas.[28]

Although not relevant at clinical dosages, bromantane has been found to produce anticholinergic effects, including both antimuscarinic and antinicotinic actions, at very high doses in animals, and these effects are responsible for its toxicity (that is, LD50) in animals.[26][29][30][31]

Pharmacokinetics

Bromantane is used clinically in doses of 50 mg to 100 mg per day in the treatment of asthenia.[7]

The main metabolite of bromantane is 6β-hydroxybromantane.[32]

Chemistry

Bromantane is an adamantane derivative. It is also known as adamantylbromphenylamine, from which its name was derived.[1]

Closely related adamantanes with similar effects include adapromine, amantadine, chlodantane, gludantane (gludantan), memantine, and rimantadine.[23]

Synthesis

Patents:[33][34] 57%:[35]

The reductive amination between Adamantanone [700-58-3] and 4-Bromoaniline [106-40-1] in the presence of formic acid gave bromantane (3).

History

In the 1960s, the adamantane derivative amantadine (1-aminoadamantane) was developed as an antiviral drug for the treatment of influenza.[36] Other adamantane antivirals subsequently followed, such as rimantadine (1-(1-aminoethyl)adamantane) and adapromine (1-(1-aminopropyl)adamantane).[5][36] It was serendipitously discovered in 1969 that amantadine possesses central dopaminergic stimulant-like properties,[37][38] and subsequent investigation revealed that rimantadine and adapromine also possess such properties.[39] Amantadine was then developed and introduced for the treatment of Parkinson's disease due to its ability to increase dopamine levels in the brain.[37] It has also notably since been used to help alleviate fatigue in multiple sclerosis.[40]

With the knowledge of the dopaminergic stimulant effects of the adamantane derivatives, bromantane, which is 2-(4-bromophenylamino) adamantane, was developed in the 1980s at the Zakusov State Institute of Pharmacology, USSR Academy of Medical Sciences (now the Russian Academy of Medical Sciences) in Moscow as "a drug having psychoactivating and adaptogen properties under complicated conditions (hypoxia, high environmental temperature, physical overfatigue, emotional stress, etc.)".[10][4] It was found to produce more marked and prolonged stimulant effects than the other adamantanes,[41] and eventually entered use.[10] The drug was notably given to soldiers in the Soviet and Russian militaries to "shorten recovery times after strong physical exertion".[10] After the break-up of the Soviet Union in 1991, bromantane continued to be researched and characterized but was mainly limited in use to sports medicine (for instance, to enhance athletic performance).[10] In 1996, it was encountered as a doping agent in the 1996 Summer Olympics when several Russian athletes tested positive for it, and was subsequently placed on the World Anti-Doping Agency banned list in 1997 as a stimulant and masking agent.[10][42]

Bromantane was eventually repurposed in 2005 as a treatment for neurasthenia.[43] It demonstrated effectiveness and safety for the treatment of the condition in extensive, large-scale clinical trials,[7] and was approved for this indication in Russia under the brand name Ladasten sometime around 2009.[8]

See also

References

  1. ^ a b "Ladasten (adamantylbromphenylamine) Tablets for Oral Use. Full Prescribing Information". Russian State Register of Medicines (in Russian). Lekko CJSC. p. 1. Archived from the original on 3 February 2016. Retrieved 27 January 2016.
  2. ^ Neild PJ, Gazzard BG (September 1997). "HIV-1 infection in China". Lancet. 350 (9082): 963. doi:10.1016/S0140-6736(05)63309-0. PMID 9314899. S2CID 40317188.
  3. ^ a b c Grekhova TV, Gainetdinov RR, Sotnikova TD, Krasnykh LM, Kudrin VS, Sergeeva SA, et al. (1995). "Effect of bromantane, a new immunostimulating agent with psychostimulating activity, on the release and metabolism of dopamine in the striatum of freely moving rats. A microdialysis study". Bulletin of Experimental Biology and Medicine. 119 (3): 294–296. doi:10.1007/BF02445840. ISSN 0007-4888. S2CID 33214442.
  4. ^ a b c d Iezhitsa IN, Spasov AA, Bugaeva LI (2001). "Effects of bromantan on offspring maturation and development of reflexes". Neurotoxicology and Teratology. 23 (2): 213–222. doi:10.1016/S0892-0362(01)00119-2. PMID 11348840.
  5. ^ a b Spasov AA, Khamidova TV, Bugaeva LI, Morozov IS (2000). "Adamantane derivatives: Pharmacological and toxicological properties (review)". Pharmaceutical Chemistry Journal. 34 (1): 1–7. doi:10.1007/BF02524549. ISSN 0091-150X. S2CID 41620120.
  6. ^ Morozov IS, Ivanova IA, Lukicheva TA (2001). "Actoprotector and Adaptogen Properties of Adamantane Derivatives (A Review)". Pharmaceutical Chemistry Journal. 35 (5): 235–238. doi:10.1023/A:1011905302667. ISSN 0091-150X. S2CID 29475883.
  7. ^ a b c d e f g h Voznesenskaia TG, Fokina NM, Iakhno NN (2010). "[Treatment of asthenic disorders in patients with psychoautonomic syndrome: results of a multicenter study on efficacy and safety of ladasten]". Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova (in Russian). 110 (5 Pt 1): 17–26. PMID 21322821.
  8. ^ a b c d e Neznamov GG, Siuniakov SA, Teleshova SE, Chumakov DV, Reutova MA, Siuniakov TS, et al. (2009). "[Ladasten, the new drug with psychostimulant and anxiolytic actions in treatment of neurasthenia (results of the comparative clinical study with placebo)]". Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova (in Russian). 109 (5): 20–26. PMID 19491814.
  9. ^ a b c d e f Mikhaylova M, Vakhitova JV, Yamidanov RS, Salimgareeva MK, Seredenin SB, Behnisch T (October 2007). "The effects of ladasten on dopaminergic neurotransmission and hippocampal synaptic plasticity in rats". Neuropharmacology. 53 (5): 601–608. doi:10.1016/j.neuropharm.2007.07.001. PMID 17854844. S2CID 43661752.
  10. ^ a b c d e f g h i Oliynyk S, Oh S (September 2012). "The pharmacology of actoprotectors: practical application for improvement of mental and physical performance". Biomolecules & Therapeutics. 20 (5): 446–456. doi:10.4062/biomolther.2012.20.5.446. PMC 3762282. PMID 24009833.
  11. ^ Tallerova AV, Kovalenko LP, Durnev AD, Seredenin SB (2011). "[Effect of antiasthenic drug ladasten on the level of cytokines and behavior in experimental model of anxious depression in C57BL/6 male mice]". Eksperimental'naia i Klinicheskaia Farmakologiia (in Russian). 74 (11): 3–5. PMID 22288152.
  12. ^ Tallerova AV, Kovalenko LP, Durnev AD, Seredenin SB (November 2011). "Effect of ladasten on the content of cytokine markers of inflammation and behavior of mice with experimental depression-like syndrome". Bulletin of Experimental Biology and Medicine. 152 (1): 58–60. doi:10.1007/s10517-011-1453-2. PMID 22803040. S2CID 23634912.
  13. ^ Tallerova AV, Kovalenko LP, Kuznetsova OS, Durnev AD, Seredenin SB (January 2014). "Correcting effect of ladasten on variations in the subpopulation composition of T lymphocytes in C57BL/6 mice on the experimental model of an anxious-depressive state". Bulletin of Experimental Biology and Medicine. 156 (3): 335–337. doi:10.1007/s10517-014-2343-1. PMID 24771370. S2CID 13007622.
  14. ^ Kuzubova EA, Bugaeva LI, Spasov AA (2004). "[The effect of bromantan on the sexual behavior and conception in rats]". Eksperimental'naia i Klinicheskaia Farmakologiia (in Russian). 67 (3): 34–37. PMID 15341065.
  15. ^ Iëzhitsa IN, Bugaeva LI, Spasov AA, Morozov IS (1999). "[The effect of the actoprotector preparation bromantane on the postnatal development of rat pups]". Eksperimental'naia i Klinicheskaia Farmakologiia (in Russian). 62 (6): 39–44. PMID 10650526.
  16. ^ a b c d Iezhitsa IN, Spasov AA, Bugaeva LI (2001). "Effects of bromantan on offspring maturation and development of reflexes". Neurotoxicology and Teratology. 23 (2): 213–222. doi:10.1016/s0892-0362(01)00119-2. PMID 11348840.
  17. ^ a b c Vakhitova YV, Yamidanov RS, Vakhitov VA, Seredenin SB (2005). "cDNA macroarray analysis of gene expression changes in rat brain after a single administration of a 2-aminoadamantane derivative". Molecular Biology. 39 (2): 244–252. doi:10.1007/s11008-005-0035-7. ISSN 0026-8933. S2CID 39459723.
  18. ^ a b c d Vakhitova I, Iamidanov RS, Seredinin SB (2004). "[Ladasten induces the expression of genes regulating dopamine biosynthesis in various structures of rat brain]". Eksperimental'naia i Klinicheskaia Farmakologiia (in Russian). 67 (4): 7–11. PMID 15500036.
  19. ^ a b c Vakhitova YV, Yamidanov RS, Vakhitov VA, Seredenin SB (2005). "The effect of ladasten on gene expression in the rat brain". Doklady. Biochemistry and Biophysics. 401 (1–6): 150–153. doi:10.1007/s10628-005-0057-z. PMID 15999825. S2CID 28048257.
  20. ^ Vakhitova I, Sadovnikov SV, Iamidanov RS, Seredenin SB (July 2006). "[Cytosine demethylation in the tyrosine hydroxylase gene promoter in the hypothalamus cells of the rat brain under the action of an aminoadamantane derivative Ladasten]". Genetika (in Russian). 42 (7): 968–975. PMID 16915929.
  21. ^ Iëzhitsa IN, Bugaeva LI, Spasov AA, Morozov IS (2000). "[Effect of bromantane on the rat neurologic status in two month course]". Eksperimental'naia i Klinicheskaia Farmakologiia (in Russian). 63 (5): 13–17. PMID 11109517.
  22. ^ a b Vakhitova I, Salimgareeva MK, Seredenin SB (2004). "[Effect of ladasten on the proteinase C activity in the rat brain cells]". Eksperimental'naia i Klinicheskaia Farmakologiia (in Russian). 67 (2): 12–15. PMID 15188752.
  23. ^ a b Morozov IS, Ivanova IA, Lukicheva TA (2001). "[Actoprotector and adaptogen properties of adamantane derivatives (a review)". Pharmaceutical Chemistry Journal. 35 (5): 235–238. doi:10.1023/A:1011905302667.
  24. ^ Danysz W, Dekundy A, Scheschonka A, Riederer P (February 2021). "Amantadine: reappraisal of the timeless diamond-target updates and novel therapeutic potentials". J Neural Transm (Vienna). 128 (2): 127–169. doi:10.1007/s00702-021-02306-2. PMC 7901515. PMID 33624170.
  25. ^ Huber TJ, Dietrich DE, Emrich HM (March 1999). "Possible use of amantadine in depression". Pharmacopsychiatry. 32 (2): 47–55. doi:10.1055/s-2007-979191. PMID 10333162.
  26. ^ a b c Morozov IS, Pukhova GS, Avdulov NA, Sergeeva SA, Spasov AA, Iezhitsa IN (1999). "[The mechanisms of the neurotropic action of bromantan]". Eksperimental'naia i Klinicheskaia Farmakologiia (in Russian). 62 (1): 11–14. PMID 10198757.
  27. ^ Zimin IA, Abaimov DA, Budygin EA, Zolotarev I, Kovalev GI (February 2010). "[Role of the brain dopaminergic and serotoninergic systems in psychopharmacological effects of ladasten and sydnocarb]". Eksperimental'naia i Klinicheskaia Farmakologiia (in Russian). 73 (2): 2–5. PMID 20369592.
  28. ^ Salimgareeva MK, Yamidanov RS, Vakhitova YV, Seredenin SB (January 2012). "Mechanisms of action of ladasten: activation of gene expression for neurotrophins and mitogen-activated kinases". Bulletin of Experimental Biology and Medicine. 152 (3): 313–317. doi:10.1007/s10517-012-1516-z. PMID 22803074. S2CID 15466533.
  29. ^ Bugaeva LI, Verovskiĭ VE, Iezhitsa IN, Spasov AA (2000). "[An acute toxicity study of bromantane]". Eksperimental'naia i Klinicheskaia Farmakologiia (in Russian). 63 (1): 57–61. PMID 10763112.
  30. ^ Iezhitsa IN, Spasov AA, Bugaeva LI, Morozov IS (April 2002). "Toxic effect of single treatment with bromantane on neurological status of experimental animals". Bulletin of Experimental Biology and Medicine. 133 (4): 380–383. doi:10.1023/a:1016206306875. PMID 12124651. S2CID 3050185.
  31. ^ Iezhitsa IN, Spasov AA, Bugaeva LI, Morozov IS (April 2002). "Toxic effect of single treatment with bromantane on neurological status of experimental animals". Bulletin of Experimental Biology and Medicine. 133 (4): 380–383. doi:10.1023/A:1016206306875. PMID 12124651. S2CID 3050185.
  32. ^ Athanasiadou I, Angelis YS, Lyris E, Vonaparti A, Thomaidis NS, Koupparis MA, et al. (January 2012). "Two-step derivatization procedures for the ionization enhancement of anabolic steroids in LC-ESI-MS for doping control analysis". Bioanalysis. 4 (2): 167–175. doi:10.4155/bio.11.308. PMID 22250799.
  33. ^ RU 1601978, Klimova NV, Zaitseva NM, Pushkartin GV, Pyatin BM, Morozovk IS, Kislyak NA, Shcherbakova OV, Bykov NP, "Method of synthesis of n-(4-bromophenyl)-n-(2-adamantyl)amine", issued 27 October 1995 
  34. ^ RU 860446, Waldman AV, Zaitseva NM, Klimova NV, Lavrova LN, Morozovn IS, Shmar MI, Shcherbakova OV, Yakubov AA, Strekalova SN, Petukhov AG, "Substituted n-adamantilanilines possessing psychostimulating activity", issued 1993, assigned to Cherkasskij Z Khimreaktivov 
  35. ^ Averin AD, Ulanovskaya MA, Kovalev VV, Buryak AK, Orlinson BS, Novakov IA, et al. (2010). "Palladium-catalyzed amination of isomeric dihalobenzenes with 1- and 2-aminoadamantanes". Russian Journal of Organic Chemistry. 46 (1): 64–72. doi:10.1134/S1070428010010069. S2CID 85441518.
  36. ^ a b Stiver HG (27 October 2006). "Treatment of Influeza". In Mandell L, Woodhead M, Ewig S, Torres A (eds.). Respiratory Infections. CRC Press. pp. 243–. ISBN 978-0-340-81694-3.
  37. ^ a b Oertel WH, Fahn S (2003). "Parkinsonism". In Brandt T (ed.). Neurological Disorders: Course and Treatment. Gulf Professional Publishing. pp. 1047–. ISBN 978-0-12-125831-3.
  38. ^ Nakamura T, Lipton SA (6 October 2009). "Excitatory Amino Acids, S-Nitrosylation, and Protein Misfolding in Neurodegenerative Diseases: Protection by Memantine and NirotMemantine at NMDA-Gated". In Channels Packer L, Sies H, Eggersdorfer M, Cadenas E (eds.). Micronutrients and Brain Health. CRC Press. pp. 71–. ISBN 978-1-4200-7352-2.
  39. ^ Krapivin SV, Sergeeva SA, Morozov IS (1998). "Comparative analysis of the effects of adapromine, midantane, and bromantane on bioelectrical activity of rat brain". Bulletin of Experimental Biology and Medicine. 125 (2): 151–155. doi:10.1007/BF02496845. ISSN 0007-4888. S2CID 21940190.
  40. ^ Gabbard GO (2007). "Dementia Due to Frontotemporal Lobar Degeneration". Gabbard's Treatments of Psychiatric Disorders. American Psychiatric Pub. pp. 174–. ISBN 978-1-58562-216-0.
  41. ^ Krapivin SV, Sergeeva SA, Morozov IS (November 1993). "[A quantitative pharmaco-electroencephalographic analysis of the action of bromantane]". Biulleten' Eksperimental'noi Biologii I Meditsiny (in Russian). 116 (11): 515–518. doi:10.1007/BF00805158. PMID 8312546. S2CID 34884133.
  42. ^ Burnat P, Payen A, Le Brumant-Payen C, Hugon M, Ceppa F (September 1997). "Bromontan, a new doping agent". Lancet. 350 (9082): 963–964. doi:10.1016/S0140-6736(05)63310-7. PMID 9314900. S2CID 34909949.
  43. ^ Siuniakov SA, Grishin SA, Teleshova ES, Neznamov GG, Seredenin SB (2006). "[Pilot clinical trial of ladasten]". Eksperimental'naia i Klinicheskaia Farmakologiia (in Russian). 69 (4): 10–15. PMID 16995430.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Bromantane&oldid=1250024883"